Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276615 | 0.91 | MAPT (0.53) | CYP19A1CYP11B1CYP11B2MAPTHSD17B1 | |
| SCHEMBL7284233 | 0.84 | ESR2 (0.61) | CYP19A1CYP11B1CYP11B2HSD17B1CYP1A2 | |
| SCHEMBL29041422 | 0.78 | MAPK10 (0.57) | CYP19A1CYP11B1CYP11B2MAPTCYP3A4 | |
| SCHEMBL152013 | 0.77 | CYP19A1 (0.45) | CYP19A1MAPTCYP1A2CYP3A4IMPDH2 | |
| SCHEMBL627219 | 0.77 | CYP1A2 (0.77) | HSD17B1CYP1A2CYP3A4ESR1ESR2 | |
| SCHEMBL29364786 | 0.77 | CYP1A2 (0.77) | HSD17B1CYP1A2CYP3A4ESR1ESR2 | |
| SCHEMBL69484 | 0.77 | CYP1A2 (0.77) | HSD17B1CYP1A2CYP3A4ESR1ESR2 | |
| SCHEMBL1651489 | 0.76 | DAO (0.50) | CYP19A1CYP3A4PDGFRBPDGFRA | |
| SCHEMBL11545398 | 0.75 | DAO (0.50) | CYP19A1CYP3A4IMPDH2ROCK2 | |
| SCHEMBL28191731 | 0.75 | PRKCZ (0.68) | CYP19A1CYP11B1CYP11B2HSD17B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | claimed |
| CN-110437062-B | Synthetic method of neratide intermediate | 成都美域高制药有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-110437062-A | It is a kind of how the synthetic method of his your intermediate of ground | CHENGDU MIRACLE PHARMACEUTICAL CO LTD | 2019-11-12 | — | — | CN | claimed |
| CN-108697709-A | Methods for treating huntington's disease | PTC医疗公司 | 2018-10-23 | — | — | CN | claimed |
| CN-107428729-A | COMPOUNDS FOR THE TREATMENT OF CANCER | 豪夫迈·罗氏有限公司 | 2017-12-01 | — | — | CN | claimed |
| CN-104562037-B | Siliceous macromolecular corrosion inhibitor composition and preparation method thereof | 中国石油化工股份有限公司 | 2017-05-17 | — | — | CN | claimed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | claimed |
| CN-104562037-A | Siliceous macromolecular corrosion inhibitor composition and preparation method thereof | CHINA PETROLEUM & CHEMICAL | 2015-04-29 | — | — | CN | claimed |
| EP-0182210-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-05-28 | — | — | EP | claimed |
| JP-7304744-A | — | — | None | — | — | JP | disclosed |
| JP-8059658-A | — | — | None | — | — | JP | disclosed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12612382-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | VALO HEALTH INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | EIKONIZO THERAPEUTICS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| EP-0266949-A1 | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane A2 antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988003137-A1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-05 | — | — | WO | disclosed |
| US-4742053-A | ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0182210-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-05-28 | — | — | EP | disclosed |
| EP-0130069-A2 | Hexahydropyrrolo (2,1-a) isoquinoline derivatives | McNeilab, Inc. (US) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | HDAC6, HDAC1, HDAC8 | CYP19A1 4433/4885CYP11B1 2529/4885CYP11B2 3057/4885 |
| US-12612382-B2 | Process for preparing 6-substituted-1-(2H)-isoquinolinones and intermediate compound | ROCK1, RHOA, ABL1 | CYP19A1 2300/4885CYP11B1 96/4885CYP11B2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.